SE Tett, BA Atcheson, PJ Taylor… - 8th World …, 2011 - espace.library.uq.edu.au The pharmacokinetics of mycophenolic acid and its glucuronide are complex. 42 renal transplant recipients receiving mycophenolate mofetil and concomitant cyclosporin (n = 32) or tacrolimus (n = 10) participated. Blood samples were taken on day 5 post-transplant. Free and total ... Cached - All 2 versions
AI Nichols, K Focht, Q Jiang… - Clinical drug …, 2011 - ingentaconnect.com A Randomized, Open-Label, Two-Period, Parallel-Group, Crossover Study ... Alice I. Nichols,1 Kristen Focht,1 Qin Jiang,1 Sheldon H. Preskorn2 and Cecelia P. Kane3 ... 1 Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, USA 2 Clinical Research ... Related articles - All 4 versions
KN Ganjoo, LD Cranmer, JE Butrynski… - Oncology, 2011 - content.karger.com Purpose: The purpose of this study was to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics and preliminary activity of TH-302, a hypoxia-activated prodrug, in combination with doxorubicin in patients with advanced soft ... Related articles - All 2 versions
Y Yamakawa, A Hamada, R Nakashima… - Therapeutic Drug …, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > Current ... Cited by 1 - Related articles - All 4 versions
P Lucidi, F Porcellati, P Rossetti… - Diabetes …, 2011 - Am Diabetes Assoc RESULTS The glucose infusion rate area under the curve 0–32 h was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05). Glargine suppressed endogenous glucose production more than detemir (P < 0.05) ... Cited by 4 - Related articles - All 3 versions